Broader Approach to HTA Could Be Used to Validate Initial Pricing Premiums: PhRMA HTA Chief

David L. Grainger, chair of PhRMA International HTA Task Force If the Japanese government is to roll out some sort of cost-effective analysis (CEA) scheme for the re-pricing of listed drugs, it could be applied to “validate” correction premiums granted...read more